FDA Accepts NDA for Otrexup for Subcutaneous Delivery of Methotrexate

Share this article:

Antares Pharma announced that the FDA has accepted for review their New Drug Application (NDA) for Otrexup, a potential new product for the SQ delivery of methotrexate (MTX) using Medi-Jet technology. Otrexup is being developed for self-administration of MTX to enhance the treatment of rheumatoid arthritis (RA), polyarticular-course juvenile RA and psoriasis.

Medi-Jet is a proprietary parenteral drug delivery system designed to enable patients to quickly and easily self-administer a drug SQ or IM, with a shielded needle that protects against accidental needle stick and drug exposure. Methotrexate is a disease-modifying anti-rheumatic (DMARD), for the treatment of RA, used in patients either on its own or in combination with biological therapies.

For more information call (763) 475-7700 or visit www.antarespharma.com
Share this article:

Related Resources

close

Next Article in Drugs in the Pipeline